Doptelet
·
- Prescription status not stated
- Blood, clotting and anaemia
- Active substance
- Avatrombopag
- Used in
- Blood, clotting and anaemia
- Made by
- Swedish Orphan Biovitrum AB (publ)
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
Details
| Made by | Swedish Orphan Biovitrum AB (publ) |
|---|---|
| Active substance | Avatrombopag |
| Used in | Blood, clotting and anaemia |
| Classification | B02BX · Blood, clotting and anaemia |
| Authorised on | 2019-06-20 |
| Last updated by the regulator | 2026-06-30 |
| EMA product number | EMEA/H/C/004722 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).